MHAUS Partner Membership

SAMBA has partnered with the Malignant Hyperthermia Association of the United States (MHAUS) to offer MHAUS membership benefits to active SAMBA members at a reduced rate. Active SAMBA members will be able to join MHAUS for just $20 per year. The SAMBA Partner Members receive the same benefits as regular members, including 30% off most educational products and events, the quarterly newsletter, “The Communicator,” and the ability to join MHAUS Awareness and Project Groups.  To join MHAUS as a SAMBA Partner Member, clickhere and select SAMBA Partner Member.

“Society for Ambulatory Anesthesia (SAMBA) has always supported the MHAUS mission and primary focus on patient safety. This partnership will formalize the cooperative relationship that SAMBA and MHAUS have enjoyed over the years, while benefiting our members and the patients they serve in a variety of practice settings including ASC’s, office-based and non-OR locations,” said Brian Parker, M.D., president of SAMBA.

“SAMBA has supported and upheld the mission of MHAUS, and has been instrumental in assuring their patients remain safe from the nightmare of MH through MH preparedness plans. The mutual respect and cooperation between our organizations is enhanced further through our joint decision to offer this partner membership option to active SAMBA members. MHAUS and SAMBA have cooperated in the past on other projects and the end results have always been positive with respect to patient safety. Those who take advantage of this opportunity will have improved access to MH education. With knowledge comes power. As a result, we expect to become even more impactful in MH preparedness efforts. The ongoing communication between SAMBA and MHAUS members and leaders can be channeled to implement products and programs that are both educational and impactful” said Dianne Daugherty, MHAUS Executive Director.

About the Malignant Hyperthermia Association of the United States (MHAUS)

MHAUS was founded by families who lost their children to MH or could not find information about MH. In 1981 they found each other – and a doctor performing MH testing – and agreed “to make current information about MH available to all who need it!”

Since 1981 MHAUS has asked fostered the following: the World Health Organization (WHO) to add MH to its list of recognized diseases and disorders. In 1983 the first MHAUS healthcare professional and patient teaching conference. In 1992 the FDA ordered pharmaceutical companies that manufacture succinylcholine to change the package insert to indicate that the drug should not be used routinely in children. In 1995 the MH 24-hour Hotline was formalized and MHAUS merged with the North American MH Registry, which had been established in 1987. In 1997 the MHAUS website was formed along with the Neuroleptic Malignant Information Service of MHAUS. In 1998 the MH ID Tag program was created. In 2000 the MH Procedure Manual was created for ambulatory surgery centers, hospitals, and office based surgery suites. In 2001 the MH Patient Liaison Committee was formed. In 2003 a new mutation in ryanodine receptor gene was discovered and appears to be causal for MH. More at:

Today MHAUS provides information and resources to medical and lay communities through conferences, educational materials, ID tags, 24-hour MH Hotline, MHAUS website, and with the help of MH Groups.

Basem B. Abdelmalak, MD, FASA

Basem B. Abdelmalak, MD, FASA is a professor of anesthesiology at Cleveland Clinic Lerner College of Medicine. He has served in the Department of General Anesthesiology as a Staff Anesthesiologist since 2001. Currently he leads Anesthesia Services for Bronchoscopic Surgery as a NORA service and is the Director of the Center for Sedation implementing the anesthesiology oversight for procedural sedation. He frequently performs the Therapeutic Whole Lung Lavage procedure to treat pulmonary alveolar proteinosis patients.

Dr. Abdelmalak is board-certified in Anesthesiology and fellowship trained in Critical Care medicine. His many clinical interests include anesthesia for ENT and bronchoscopic surgery, difficult airway management.

He served the Ohio Society of Anesthesiologists as its president in 2015 and currently serves the American Society of Anesthesiologists (ASA) as the Vice-chair of the educational track subcommittee on Ambulatory Anesthesia, the Society for Head and Neck Anesthesia (SHANA), as a founding member, and its president

At the Society for Ambulatory Anesthesia (SAMBA) he served in many roles and capacities; as a member of the committees on the Annual meeting, NORA, and Finance, and chair of the Development committee for the past 7 years leading SAMBA’s relationships with corporate sponsors, and pharmaceutical and industrial supporters. He then served on the Board of Directors, as a director, Vice President, President –elect, and now as its President.

He is also a part of the Anesthesiology Outcomes Research Department. His research interest is focused on the study of perioperative glycemic management, and he has been the primary investigator of many research projects investigating this and other topics.

He has received numerous honors and awards, including being named one of America’s Top Anesthesiologists according to the Consumers’ Research Council of America and Safety Champion by the Cleveland Clinic Quality Institute. A frequently invited lecturer at national and international conferences, Dr. Abdelmalak authored many scientific articles and book chapters in his field, and recently co-edited two textbooks titled Anesthesia for Otolaryngologic Surgery and Clinical Airway Management; An Illustrated Case Based Approach by Cambridge University Press.  He continues to be heavily involved with the education and training of medical students and residents and recently received the Scholarship in Teaching Award from Case Western Reserve University.